Therefore, following our seminal contribution on the use of tertiary benzene sulphonamides as selective cancer-related hCAs inhibitors, we considered that fluoroenesulphonamide group could represent an interesting novel selective chemotype and evaluated the activity of this new series against hCA I, hCA II, hCA IX and hCA XII. The gene discussed is CYP24A1; the disease is cancer.